Which of these NASH-oriented biotechs is the better buy?
News & Analysis: Intercept Pharmaceuticals
With stock valuations down and out, the timing may be ripe for pharma and big biotech companies to start bargain hunting.
Which stock wins in a matchup between an up-and-coming biotech and a longtime biotech leader?
The biotech rivals each aim to dominate the treatment market for non-alcoholic steatohepatitis (NASH).
If you're looking for market-crushing returns, you've come to the right place.
ICPT earnings call for the period ending June 30, 2019.
The drugmaker reported strong sales growth for Ocaliva as it prepares to file for approval in what could be a blockbuster indication.
Find out which stocks have our team of healthcare experts feeling excited right now.
Which stock wins in a battle between an up-and-coming biotech and a hemp CBD leader?
These three biotech stocks should turn out to be outstanding long-term growth vehicles.